Company intelligence / Profile preview

Ondek

Crawley, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

Ondek demonstrated proof-of-concept for its proprietary Pylori Platform HPPT for novel oral vaccine and drug delivery using genetically engineered Helicobacter pylori. However, as of latest available data, the company remains preclinical without published clinical trial results or late-stage pipeline and is reported to be inactive/closed.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Live biotherapeutic product therapyVaccineBiologicDrug delivery platform
Industry: Biotech

Beyond the preview

Go deeper on Ondek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ondek.

Explore the full profile